title: Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen.
abstract: Leukocytes in blood and spleen can be activated by interleukin 2 (IL-2) to become cytotoxic to certain tumor cell lines in vitro. Recent evidence suggests that such lymphokine-activated killer (LAK) cells can bring about the regression of solid tumors in animals and patients, under certain circumstances. Here, Ronald Herberman and colleagues from eight international laboratories, review what is known of the characteristics of LAK cell activity and conclude that most of it can be attributed to natural killer cells stimulated by IL-2.
authors.affiliation: Pittsburgh Cancer Institute and Departments of Medicine and Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Herberman
authors.affiliation: Pittsburgh Cancer Institute and Departments of Medicine and Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
authors.forename: J
authors.initials: J
authors.lastname: Hiserodt
authors.affiliation: Pittsburgh Cancer Institute and Departments of Medicine and Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
authors.forename: N
authors.initials: N
authors.lastname: Vujanovic
authors.affiliation: Department of General Surgery, MD Anderson Hospital and Tumor Institute, Houston, TX 77030, USA.
authors.forename: C
authors.initials: C
authors.lastname: Balch
authors.affiliation: Department of General Surgery, MD Anderson Hospital and Tumor Institute, Houston, TX 77030, USA.
authors.forename: E
authors.initials: E
authors.lastname: Lotzova
authors.affiliation: Department of Immunology, Dr Daniel den Hoed Cancer Center, 3008 AE Rotherdam, The Netherlands.
authors.forename: R
authors.initials: R
authors.lastname: Bolhuis
authors.affiliation: Department of Surgery, Division of Oncology, UCLA School of Medicine, University of California, Los Angeles, CA 90024, USA.
authors.forename: S
authors.initials: S
authors.lastname: Golub
authors.affiliation: Becton Dickinson Monoclonal Center, Mountain View, CA 94043, USA.
authors.forename: L L
authors.initials: LL
authors.lastname: Lanier
authors.affiliation: Becton Dickinson Monoclonal Center, Mountain View, CA 94043, USA.
authors.forename: J H
authors.initials: JH
authors.lastname: Phillips
authors.affiliation: Institute of Pharmacology, University of Perugia, Perugia, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Riccardi
authors.affiliation: Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
authors.forename: J
authors.initials: J
authors.lastname: Ritz
authors.affiliation: Universita degli Stude 'Sapienze', Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Santoni
authors.affiliation: Departments of Medicine and Clinical Immunology, Medizinische Hochschule Hannover, D-3000 Hannover 61, Fed. Rep. Germany.
authors.forename: R E
authors.initials: RE
authors.lastname: Schmidt
authors.affiliation: Department of Radiation System Biology, Radiation Biology Center, Kyoto University, Kyoto 606, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Uchida